Chinese General Practice ›› 2024, Vol. 27 ›› Issue (35): 4403-4411.DOI: 10.12114/j.issn.1007-9572.2023.0441
• Original Research • Previous Articles Next Articles
Received:
2023-10-03
Revised:
2024-04-11
Published:
2024-12-15
Online:
2024-09-13
Contact:
GOU Lianping
通讯作者:
苟连平
作者简介:
罗琴负责研究目标的提出,项目构思及设计,数据收集,论文撰写;苟连平整体负责文章的质量控制与审查,并对文章整体进行监督管理;罗琴、陈银负责绘制统计学图表;苏凤进行论文的修订。
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0441
组别 | 例数 | 性别(男/女) | BMI ( | ASMI[M(P25,P75),kg/m2] | ASM[M(P25,P75),kg] | 骨骼肌量[M(P25,P75),kg] | 握力[M(P25,P75),kg] | 年龄[M(P25,P75),岁] | 体质量[M(P25,P75),kg] |
---|---|---|---|---|---|---|---|---|---|
非肌少症组 | 155 | 99/56 | 23.4±2.8 | 7.36(6.63,7.99) | 19.8(16.0,22.1) | 26.1(21.6,29.3) | 20(16,24) | 71(67,77) | 59.8(55.6,65.9) |
肌少症组 | 58 | 37/21 | 20.2±2.5 | 6.45(5.59,6.82) | 16.6(12.9,18.2) | 21.8(18.6,23.6) | 24(19,28) | 74(69,78) | 51.4(46.0,57.2) |
检验统计量值 | <0.001a | -7.563b | -7.775 | -6.271 | -5.937 | -4.214 | -1.500 | -6.745 | |
P值 | 0.992 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.134 | <0.001 | |
组别 | 身高[M(P25,P75),cm] | 上臂围[M(P25,P75),cm] | 小腿围[M(P25,P75),cm] | 上臂除脂周长[M(P25,P75),cm] | Ishii评分[M(P25,P75),分] | RBC[M(P25,P75),×1012/L] | PLT[M(P25,P75),×109/L] | 白蛋白[M(P25,P75),g/L] | |
非肌少症组 | 160(156,167) | 29.2(27.9,31.0) | 34.0(33.8,35.0) | 24.7(23.3,26.5) | 111.92(101.01,124.01) | 4.2(3.8,4.6) | 167(126,208) | 39.8(37.8,42.2) | |
肌少症组 | 160(155,165) | 26.9(24.8,28.0) | 33.0(32.0,33.5) | 22.5(20.9,23.4) | 131.56(123.20,142.80) | 4.3(3.8,4.6) | 186(148,241) | 39.7(38.5,41.2) | |
检验统计量值 | -2.094 | -2.649 | -7.110 | -7.223 | -7.038 | -0.091 | -2.470 | -0.164 | |
P值 | 0.036 | 0.008 | <0.001 | <0.001 | <0.001 | 0.928 | 0.014 | 0.870 | |
组别 | Cr[M(P25,P75),µmol/L] | AST[M(P25,P75),U/L] | ALT[M(P25,P75),U/L] | TSH[M(P25,P75),U/L] | TC[M(P25,P75),mmol/L] | HDL-C( | TG[M(P25,P75),mmol/L] | D-二聚体[M(P25,P75),mg/L] | |
非肌少症组 | 78.6(65.9,101.2) | 24(20,32) | 22(16,33) | 2.20(1.30,3.10) | 3.85(3.17,4.64) | 1.06±0.28 | 1.17(0.84,1.75) | 0.82(0.65,1.08) | |
肌少症组 | 71.0(60.8,86.0) | 24(19,30) | 21(13,29) | 1.83(1.09,3.46) | 4.04(3.56,4.42) | 1.25±0.35 | 1.08(0.80,1.46) | 0.80(0.65,1.24) | |
检验统计量值 | -2.334 | -1.610 | -0.804 | -0.347 | -1.277 | 3.410b | -1.229 | -0.225 | |
P值 | 0.020 | 0.872 | 0.421 | 0.728 | 0.202 | <0.001 | 0.219 | 0.822 |
Table 1 Comparison of general data between sarcopenia group and non-sarcopenia group
组别 | 例数 | 性别(男/女) | BMI ( | ASMI[M(P25,P75),kg/m2] | ASM[M(P25,P75),kg] | 骨骼肌量[M(P25,P75),kg] | 握力[M(P25,P75),kg] | 年龄[M(P25,P75),岁] | 体质量[M(P25,P75),kg] |
---|---|---|---|---|---|---|---|---|---|
非肌少症组 | 155 | 99/56 | 23.4±2.8 | 7.36(6.63,7.99) | 19.8(16.0,22.1) | 26.1(21.6,29.3) | 20(16,24) | 71(67,77) | 59.8(55.6,65.9) |
肌少症组 | 58 | 37/21 | 20.2±2.5 | 6.45(5.59,6.82) | 16.6(12.9,18.2) | 21.8(18.6,23.6) | 24(19,28) | 74(69,78) | 51.4(46.0,57.2) |
检验统计量值 | <0.001a | -7.563b | -7.775 | -6.271 | -5.937 | -4.214 | -1.500 | -6.745 | |
P值 | 0.992 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.134 | <0.001 | |
组别 | 身高[M(P25,P75),cm] | 上臂围[M(P25,P75),cm] | 小腿围[M(P25,P75),cm] | 上臂除脂周长[M(P25,P75),cm] | Ishii评分[M(P25,P75),分] | RBC[M(P25,P75),×1012/L] | PLT[M(P25,P75),×109/L] | 白蛋白[M(P25,P75),g/L] | |
非肌少症组 | 160(156,167) | 29.2(27.9,31.0) | 34.0(33.8,35.0) | 24.7(23.3,26.5) | 111.92(101.01,124.01) | 4.2(3.8,4.6) | 167(126,208) | 39.8(37.8,42.2) | |
肌少症组 | 160(155,165) | 26.9(24.8,28.0) | 33.0(32.0,33.5) | 22.5(20.9,23.4) | 131.56(123.20,142.80) | 4.3(3.8,4.6) | 186(148,241) | 39.7(38.5,41.2) | |
检验统计量值 | -2.094 | -2.649 | -7.110 | -7.223 | -7.038 | -0.091 | -2.470 | -0.164 | |
P值 | 0.036 | 0.008 | <0.001 | <0.001 | <0.001 | 0.928 | 0.014 | 0.870 | |
组别 | Cr[M(P25,P75),µmol/L] | AST[M(P25,P75),U/L] | ALT[M(P25,P75),U/L] | TSH[M(P25,P75),U/L] | TC[M(P25,P75),mmol/L] | HDL-C( | TG[M(P25,P75),mmol/L] | D-二聚体[M(P25,P75),mg/L] | |
非肌少症组 | 78.6(65.9,101.2) | 24(20,32) | 22(16,33) | 2.20(1.30,3.10) | 3.85(3.17,4.64) | 1.06±0.28 | 1.17(0.84,1.75) | 0.82(0.65,1.08) | |
肌少症组 | 71.0(60.8,86.0) | 24(19,30) | 21(13,29) | 1.83(1.09,3.46) | 4.04(3.56,4.42) | 1.25±0.35 | 1.08(0.80,1.46) | 0.80(0.65,1.24) | |
检验统计量值 | -2.334 | -1.610 | -0.804 | -0.347 | -1.277 | 3.410b | -1.229 | -0.225 | |
P值 | 0.020 | 0.872 | 0.421 | 0.728 | 0.202 | <0.001 | 0.219 | 0.822 |
性别 | 诊断指标 | AUC | 95%CI | P值 | 最佳截断值 | 约登指数 | 灵敏度(%) | 特异度(%) |
---|---|---|---|---|---|---|---|---|
男 | Ishii评分 | 0.818 | 0.749~0.888 | <0.001 | 114.07分 | 0.545 | 91.9 | 62.6 |
上臂围 | 0.841 | 0.768~0.915 | <0.001 | 28.0 cm | 0.562 | 70.3 | 85.9 | |
小腿围 | 0.854 | 0.788~0.920 | <0.001 | 34.3 cm | 0.511 | 86.5 | 64.6 | |
女 | Ishii评分 | 0.812 | 0.719~0.904 | <0.001 | 120.08分 | 0.643 | 100.0 | 64.3 |
上臂围 | 0.797 | 0.692~0.901 | <0.001 | 27.5 cm | 0.506 | 81.0 | 69.6 | |
小腿围 | 0.835 | 0.746~0.924 | <0.001 | 33.8 cm | 0.500 | 100.0 | 50.0 |
Table 2 Evaluative value of Ishii score,calf circumference and upper arm circumference in the diagnosis of sarcopenia
性别 | 诊断指标 | AUC | 95%CI | P值 | 最佳截断值 | 约登指数 | 灵敏度(%) | 特异度(%) |
---|---|---|---|---|---|---|---|---|
男 | Ishii评分 | 0.818 | 0.749~0.888 | <0.001 | 114.07分 | 0.545 | 91.9 | 62.6 |
上臂围 | 0.841 | 0.768~0.915 | <0.001 | 28.0 cm | 0.562 | 70.3 | 85.9 | |
小腿围 | 0.854 | 0.788~0.920 | <0.001 | 34.3 cm | 0.511 | 86.5 | 64.6 | |
女 | Ishii评分 | 0.812 | 0.719~0.904 | <0.001 | 120.08分 | 0.643 | 100.0 | 64.3 |
上臂围 | 0.797 | 0.692~0.901 | <0.001 | 27.5 cm | 0.506 | 81.0 | 69.6 | |
小腿围 | 0.835 | 0.746~0.924 | <0.001 | 33.8 cm | 0.500 | 100.0 | 50.0 |
筛查工具 | AUC | 95%CI | P值 | 灵敏度(%) | 特异度(%) | 阳性预测值(%) | 阴性预测值(%) |
---|---|---|---|---|---|---|---|
Ishii评分 | 0.814 | 0.758~0.869 | <0.001 | 29.3 | 90.3 | 53.1 | 77.3 |
上臂围 | 0.814 | 0.752~0.875 | <0.001 | 36.2 | 92.9 | 65.6 | 82.3 |
小腿围 | 0.813 | 0.752~0.874 | <0.001 | 41.4 | 92.9 | 68.6 | 78.6 |
Table 3 Comparison of the accuracy of Ishii score,calf circumference and upper arm circumference in the diagnosis of sarcopenia
筛查工具 | AUC | 95%CI | P值 | 灵敏度(%) | 特异度(%) | 阳性预测值(%) | 阴性预测值(%) |
---|---|---|---|---|---|---|---|
Ishii评分 | 0.814 | 0.758~0.869 | <0.001 | 29.3 | 90.3 | 53.1 | 77.3 |
上臂围 | 0.814 | 0.752~0.875 | <0.001 | 36.2 | 92.9 | 65.6 | 82.3 |
小腿围 | 0.813 | 0.752~0.874 | <0.001 | 41.4 | 92.9 | 68.6 | 78.6 |
性别 | 筛查工具 | 2023肌少症共识 | 合计 | Kappa值 | P值 | ||
---|---|---|---|---|---|---|---|
是 | 否 | ||||||
男性 | 小腿围 | (+) | 32 | 35 | 67 | 0.408 | <0.001 |
(-) | 5 | 64 | 69 | ||||
上臂围 | (+) | 26 | 14 | 40 | 0.547 | <0.001 | |
(-) | 11 | 85 | 96 | ||||
Ishii评分 | (+) | 34 | 37 | 71 | 0.423 | <0.001 | |
(-) | 3 | 62 | 65 | ||||
女性 | 小腿围 | (+) | 21 | 28 | 49 | 0.353 | <0.001 |
(-) | 0 | 28 | 28 | ||||
上臂围 | (+) | 17 | 17 | 34 | 0.424 | <0.001 | |
(-) | 4 | 39 | 43 | ||||
Ishii评分 | (+) | 21 | 20 | 41 | 0.495 | <0.001 | |
(-) | 0 | 36 | 36 |
Table 4 Results of the consistency test of Ishii score,calf circumference and upper arm circumference with the diagnostic criteria of Chinese expert consensus (2023) criteria for the prevention and treatment of sarcopenia in the elderly
性别 | 筛查工具 | 2023肌少症共识 | 合计 | Kappa值 | P值 | ||
---|---|---|---|---|---|---|---|
是 | 否 | ||||||
男性 | 小腿围 | (+) | 32 | 35 | 67 | 0.408 | <0.001 |
(-) | 5 | 64 | 69 | ||||
上臂围 | (+) | 26 | 14 | 40 | 0.547 | <0.001 | |
(-) | 11 | 85 | 96 | ||||
Ishii评分 | (+) | 34 | 37 | 71 | 0.423 | <0.001 | |
(-) | 3 | 62 | 65 | ||||
女性 | 小腿围 | (+) | 21 | 28 | 49 | 0.353 | <0.001 |
(-) | 0 | 28 | 28 | ||||
上臂围 | (+) | 17 | 17 | 34 | 0.424 | <0.001 | |
(-) | 4 | 39 | 43 | ||||
Ishii评分 | (+) | 21 | 20 | 41 | 0.495 | <0.001 | |
(-) | 0 | 36 | 36 |
研究 | 性别 | 2023肌少症共识 | 合计 | Kappa值 | P值 | ||
---|---|---|---|---|---|---|---|
是 | 否 | ||||||
Ishii研究 | 男性 | (+) | 37 | 64 | 101 | 0.229 | <0.001 |
(-) | 0 | 35 | 35 | ||||
女性 | (+) | 21 | 21 | 42 | 0.476 | <0.001 | |
(-) | 0 | 35 | 35 | ||||
本研究 | 男性 | (+) | 34 | 37 | 71 | 0.423 | <0.001 |
(-) | 3 | 62 | 65 | ||||
女性 | (+) | 21 | 20 | 41 | 0.495 | <0.001 | |
(-) | 0 | 36 | 36 |
Table 5 Comparison of the effect of two Ishii cut-off values in determining sarcopenia
研究 | 性别 | 2023肌少症共识 | 合计 | Kappa值 | P值 | ||
---|---|---|---|---|---|---|---|
是 | 否 | ||||||
Ishii研究 | 男性 | (+) | 37 | 64 | 101 | 0.229 | <0.001 |
(-) | 0 | 35 | 35 | ||||
女性 | (+) | 21 | 21 | 42 | 0.476 | <0.001 | |
(-) | 0 | 35 | 35 | ||||
本研究 | 男性 | (+) | 34 | 37 | 71 | 0.423 | <0.001 |
(-) | 3 | 62 | 65 | ||||
女性 | (+) | 21 | 20 | 41 | 0.495 | <0.001 | |
(-) | 0 | 36 | 36 |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
张新超,于学忠,陈凤英,等. 急性冠脉综合征急诊快速诊治指南(2019)[J]. 中华急诊医学杂志,2019,28(4):421-421. DOI:10.3760/cma.j.issn.1671-0282.2019.04.003.
|
[8] |
|
[9] |
张宁,朱文玲,刘晓红,等. 住院老年冠心病患者合并肌少症的相关因素分析[J]. 中华心血管病杂志,2019,47(12):979-984. DOI:10.3760/cma.j.issn.0253-3758.2019.12.007.
|
[10] |
谢素香,叶建华,吕新芝,等.老年冠心病患者肌少症患病率及对患者短期预后的影响[J].重庆医学,2022,51(11):1866-1870. DOI:10.3969/j.issn.1671-8348.2022.11.013.
|
[11] |
王茜婷,刘梅林. 老年冠心病患者合并肌肉减少症的相关性研究[J].临床心血管病杂志,2018,34(12):1182-1186. DOI:10.13201/j.issn.1001-1439.2018.12.008.
|
[12] |
|
[13] |
崔华,王朝晖,吴剑卿,等. 老年人肌少症防控干预中国专家共识(2023)[J]. 中华老年医学杂志,2023,42(2):144-153. DOI:10.3760/cma.j.issn.0254-9026.2023.02.002.
|
[14] |
|
[15] |
|
[16] |
|
[17] | |
[18] |
|
[19] |
|
[20] |
陈巧聪,楼慧玲,彭程,等. 中老年人骨折风险与握力、步速、肌肉量的相关性[J]. 实用医学杂志,2020,36(1):69-73. DOI:10.3969/j.issn.1006-5725.2020.01.013.
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[26] |
|
[27] |
何清华,王秀芝,杨彩哲,等. 上臂围用于评估老年2型糖尿病患者低肌肉含量的临床价值[J]. 中华糖尿病杂志,2023,15(1):14-19. DOI:10.3760/cma.j.cn115791-20220530-00244.
|
[28] |
|
[29] |
|
[30] |
|
[31] |
|
[32] |
|
[33] |
|
[34] |
黄倩,徐慧萍,张艳,等. 社区慢性病共病老年患者肌少症筛查工具的比较研究[J]. 中华护理杂志,2022,57(24):3017-3021. DOI:10.3761/j.issn.0254-1769.2022.24.011.
|
[35] |
杜晓菊,张海林,尹丽霞,等. 小腿围在评估维持性血液透析患者骨骼肌质量下降中的效果研究[J]. 中华护理杂志,2021,56(8):1187-1193. DOI:10.3761/j.issn.0254-1769.2021.08.011.
|
[36] |
吴振云,钮美娥,韩燕霞,等. 小腿围筛查稳定期男性COPD患者骨骼肌消耗研究[J]. 护理学杂志,2023,38(2):30-33. DOI:10.3870/j.issn.1001-4152.2023.02.030.
|
[37] |
|
[38] |
|
[39] |
|
[40] |
黄姣玲,华楠,姚雪梅,等. Ishii评分在养老机构老年人肌少症筛查中的应用[J]. 护理学杂志,2023,38(4):100-103. DOI:10.3870/j.issn.1001-4152.2023.04.100.
|
[1] | SUN Xuechun, DU Zhiyong, YU Huahui, LYU Qianwen, JIAO Xiaolu, WANG Yu, QIN Yanwen. Value of Lysophospholipid Metabolites in Prognosis of Major Adverse Cardiac Events in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: a Prospective Cohort Study [J]. Chinese General Practice, 2024, 27(36): 4540-4545. |
[2] | ZHANG Shuo, ZHANG Long, ZHANG Yan, LI Jianping. Advances in Molecular Biotechnology for Diagnosing and Treating Familial Hypercholesterolemia [J]. Chinese General Practice, 2024, 27(36): 4498-4504. |
[3] | LI Yuan, MA Hongyang, LI Biao, YUE Anna, SHAO Yaqing, SUN Kangyun. Clinical Significance of Screening for Familial Hypercholesterolemia in Patients with Hypercholesterolemia [J]. Chinese General Practice, 2024, 27(36): 4515-4521. |
[4] | ZHU Suyan, ZHENG Xiaomeng, FAN Miao, CHEN Chunyan. Interpretation of the Screening Tool of Older Person's Potentially Inappropriate Prescriptions/Screening Tool to Alert to Right Treatment (STOPP/START) Criteria (Version 3) [J]. Chinese General Practice, 2024, 27(33): 4097-4104. |
[5] | ZHOU Zhensen, HUANG Yan, CHENG Siwei, ZHANG Xiaoyu, ZHANG Xiaoyu, SUN Ting, YANG Xianjun, XIE Hui, MA Zuchang. Construction and Validation of a Screening Model for Early Atherosclerosis Risk in the Aorta [J]. Chinese General Practice, 2024, 27(33): 4147-4154. |
[6] | JIA Gaopeng, QU Ze, LI Guimei, HUANGFU Weizhong, ZHAO Zihao, YAN Shuang, CHEN Qiuyu, ZHANG Yue. Effectiveness and Safety of Drug-coated Balloons in Treating De Novo Lesions in Large Coronary Vessels of Elderly Patients: a Cohort Study [J]. Chinese General Practice, 2024, 27(33): 4125-4131. |
[7] | MA Yuxia, YANG Yiyi, WEI Xiaoqin, CHEN Yanru, QIN Jiangxia, YUAN Yue, CHEN Yajing, WU Yinping, HAN Lin. The Accuracy of Screening for Post-stroke Cognitive Impairment Assessment Tools: a Meta-analysis [J]. Chinese General Practice, 2024, 27(32): 4066-4076. |
[8] | Diabetes and Microcirculation Professional Committee of Chinese Society of Microcirculation, Primary Endocrine and Metabolic Diseases Group of the Chinese Society of Endocrinology. Expert Consensus on Screening and Prevention of Diabetic Microvascular Disease for Primary Care (2024) [J]. Chinese General Practice, 2024, 27(32): 3969-3986. |
[9] | CHEN Muxin, LIANG Hao, ZHAO Yidi, YANG Xiaomin, FANG Jiamin, ZHOU Chunjiao, FU Xiuzhen, WEI Lin. Effectiveness Comparison of Different Frailty Assessment Tools in Preoperative Frailty Screening in the Elderly [J]. Chinese General Practice, 2024, 27(30): 3790-3796. |
[10] | GAO Yixuan, WANG Xiyou, CHEN Qianji, YANG Xiaoming, GUO Junming, ZI Yilu, WENG Zhiwen, MA Jingyi, ZHANG Naiwen, LIU Eryang, SHAO Hui, SUN Yanan, YU Changhe. Roland-Morris Disability Questionnaire Measurement Performance Evidence in Chinese Patients with Low Back Pain: a Systematic Review Based on COSMIN Guidelines [J]. Chinese General Practice, 2024, 27(29): 3672-3678. |
[11] | ZHANG Peng, LIU Lidi, YANG Ziyu, YANG Rong, LYU Yao, ZHOU Yiheng, FANG Xiang, LEI Yi, DAI Hua, LIAO Xiaoyang. Interpretation of the 2023 Recommendation Statement by the U.S. Preventive Services Task Force on the Screening for Hypertensive Disorders of Pregnancy [J]. Chinese General Practice, 2024, 27(29): 3581-3586. |
[12] | LI Yong, LI Zhanhu, JIN Bowei, LI Yuan, ZHANG Hongbo, SU Yakun, YAN Xiaoju. Correlation between Serum Complement C1q/Tumor Necrosis Factor-related Protein 5 Levels and the Severity of Coronary Artery Lesions and Myocardial Fibrosis Markers in Patients with Acute Coronary Syndrome [J]. Chinese General Practice, 2024, 27(27): 3365-3371. |
[13] | YAO Shanshan, MA Zhuyue, SHI Yanyan, WU Yuqing, ZHANG Liuliu, CHEN Mingxia, WU Bing, CHENG Fang. Development and Reliability and Validity Test of Cardiotoxicity Risk Assessment Scale for Breast Cancer Patients Undergoing Chemotherapy [J]. Chinese General Practice, 2024, 27(27): 3428-3434. |
[14] | WANG Kaiyang, YU Xiaolin, MA Ling, TAO Jing, YONG Jiahui, YANG Yining. Impact of Thyroid Dysfunction on Cardiac Structure and Function in Patients with Coronary Artery Disease Post-percutaneous Coronary Intervention: a Large Single-center Retrospective Cohort Study [J]. Chinese General Practice, 2024, 27(27): 3351-3358. |
[15] | GAO Min, SUN Guozhen, WANG Qianyi, WANG Jie, HUANG Yangxi, YU Tianxi, LIU Shenxinyu, WEN Gaoqin. Development of Exercise Rehabilitation Adherence Scale for Patients with Chronic Heart Failure and Test on Its Reliability and Validity [J]. Chinese General Practice, 2024, 27(25): 3150-3158. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||